Investor Presentaiton slide image

Investor Presentaiton

2021 Outlook Targeting 29-33% billings growth at constant currencies Billings (non-IFRS) Revenue (IFRS) 2020 Guidance 2020 Actual 2021 Outlook (*excl. Ubimax) (incl. Ubimax) €450-455m* €460.3m¹ €585-605m at least €450m* €455.6m² €525 – 540m Adj. EBITDA Margin (non-IFRS, as % of Billings) around 56% 56.8% 55-57% Capital Expenditure (excl. M&A) €25-30m €26.2m Ubimax contribution of €3.6m 2 Ubimax contribution of €2.9m 19 Q4/ FY 2020 Preliminary Results (unaudited) - Investor Presentation With c.30% USD denominated billings and exposure to other currencies, reported growth is subject to exchange rate changes Outlook assumes USD/EUR exchange rate of 1.20 and broadly stable other currencies Billings outlook corresponds to 29 - 33% growth at constant currencies Revenue below billings as remaining perpetual deferred revenue has been largely recognized Investments to continue in 2021 within financial model, with a greater focus on marketing initiatives Following one-off investments in 2020, capital expenditure returning to a lower level TeamViewer
View entire presentation